U.S. warns Novartis on Alzheimer's drug promotion
WASHINGTON (Reuters) - A Novartis AG promotion for Alzheimer's drug Exelon made misleading claims about the medicine's effectiveness and risks, U.S. health officials warned the company in a letter released on Tuesday. (Source: Reuters: Health)

Rivastigmine in the treatment of Alzheimer’s disease: an update
Maria Luisa Onor, Marianna Trevisiol, Eugenio AgugliaDepartment of Clinical, Morphological and Technological Sciences, U.C.O. of Clinical Psychiatry, University of Trieste, Trieste, ItalyAbstract: Alzheimerrsquo;s disease is the most common form of dementia in industrialized countries. In the European Union, about 54% of dementia cases are believed to be due to Alzheimerrsquo;s disease. The condition is an age-related neurodegenerative disorder characterized by multiple cognitive deficiencies, including loss of memory, judgment, and comprehension. These manifestations are accompanied by behavioral and mood disturbances. Although no cure has yet been discovered for Alzheimerrsquo;s disease, symptomatic therapies are now widely available and offer significant relief to patients and benefi...